Literature DB >> 23349368

Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology.

Richard M Cubbon1, Brook Adams, Adil Rajwani, Ben N Mercer, Peysh A Patel, Guy Gherardi, Christopher P Gale, Phillip D Batin, Ramzi Ajjan, Lorraine Kearney, Stephen B Wheatcroft, Robert J Sapsford, Klaus K Witte, Mark T Kearney.   

Abstract

BACKGROUND: It is unclear whether diabetes mellitus (DM) is an adverse prognostic factor in chronic heart failure (CHF) of ischaemic and non-ischaemic aetiology managed with contemporary evidence-based care.
METHODS: In total, 1091 outpatients with CHF with reduced ejection fraction were prospectively observed for a mean of 960 days. Total and cardiovascular mortality was quantified after accounting for potential confounders.
RESULTS: In total, 25.7% of patients had DM; this group was more likely to have CHF of ischaemic aetiology and was more symptomatic. Patients with DM received comparable medical- and device-based therapies, except for greater doses of loop diuretic. DM was associated with approximately doubled crude and adjusted risk of total and cardiovascular mortality. The association of diabetes with these outcomes in patients with ischaemic and non-ischaemic cardiomyopathies was of similar magnitude.
CONCLUSIONS: In spite of advances in the management of CHF, DM remains a major adverse prognostic feature, irrespective of ischaemic/non-ischaemic aetiology.

Entities:  

Keywords:  Chronic heart failure; aetiology; diabetes mellitus; mortality

Mesh:

Year:  2013        PMID: 23349368     DOI: 10.1177/1479164112471064

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  45 in total

1.  Diabetes mellitus and heart failure: a deadly duo.

Authors:  Michael Drozd; Mark T Kearney
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

2.  Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study.

Authors:  Malene N Demant; Gunnar H Gislason; Lars Køber; Allan Vaag; Christian Torp-Pedersen; Charlotte Andersson
Journal:  Diabetologia       Date:  2014-05-22       Impact factor: 10.122

3.  Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.

Authors:  Celestino Sardu; Raffaele Marfella; Gaetano Santulli
Journal:  J Cardiovasc Transl Res       Date:  2014-02-06       Impact factor: 4.132

4.  Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes.

Authors:  Sandra B Dunbar; Carolyn M Reilly; Rebecca Gary; Melinda K Higgins; Steven Culler; Brittany Butts; Javed Butler
Journal:  J Card Fail       Date:  2015-05-29       Impact factor: 5.712

5.  Cardio-renal protection with empagliflozin.

Authors:  Richard J MacIsaac; George Jerums; Elif I Ekinci
Journal:  Ann Transl Med       Date:  2016-10

Review 6.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

Review 7.  Impact of empagliflozin in patients with diabetes and heart failure.

Authors:  David Pham; Natalia De Albuquerque Rocha; Darren K McGuire; Ian J Neeland
Journal:  Trends Cardiovasc Med       Date:  2016-08-04       Impact factor: 6.677

Review 8.  Cardioprotective diabetes drugs: what cardiologists need to know.

Authors:  Jenifer M Brown; Brendan M Everett
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-11-13

Review 9.  [Sudden cardiac death in diabetes mellitus].

Authors:  C W Israel; Y H Lee-Barkey
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

Review 10.  Devices in heart failure; diagnosis, detection and disease modification.

Authors:  John Gierula; Mark T Kearney; Klaus K Witte
Journal:  Br Med Bull       Date:  2018-03-01       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.